Uveitis Treatment Trials—A Cross-study Perspective

Figures & data

Table 1  Kaplan-Meier estimates of the proportion of patients (95% confidence intervals) with control of inflammation and control of inflammation plus corticosteroid-sparing success as reported at various time points across different studies.

Study	Control of inflammation^a			Control of inflammation^a plus corticosteroid sparing success^b				Discontinuation rate/person-year (PY)^c
	3 months (%)	6 months (%)	12 months (%)	24 months (%)	3 months (%)	6 months (%)	12 months (%)
SITE Study Group^d—Azathioprine^Citation17		57 (46–69)	73 (61–83)			32 (24–43)	47 (37–58)	0.45/PY (0.37/PY–0.55/PY)
SITE Study Group—Methotrexate^Citation18		63 (56–70)	74 (68–80)			37 (32–43)	58 (52–65)	0.42/PY (0.37/PY–0.49/PY)
SITE Study Group—Cyclophosphamide^Citation19		59 (51–67)	83 (75–90)			30 (24–38)	61 (53–70)	0.85/PY (0.72–0.99)
SITE Study Group—Cyclosporine^Citation20		61 (54–68)	76 (70–83)			22 (18–27)	36 (31–42)	0.26/PY (0.23/PY–0.31/PY)
SITE Study Group—Mycophenolate mofetil^Citation21		78 (68–86)	91 (83–97)			41 (34–49)	55 (47–64)	0.28/PY (0.22/PY–0.35/PY)
MUST Trial Research Group^e—Fluocinolone acetonide 0.59mg (Retisert®)	74 (66–82)	79 (71–86)	85 (78–90)	88 (80–94)
MUST Trial Research Group—Systemic Therapy^Citation24	53 (43–63)	56 (46–65)	64 (55–74)	71 (61–79)
Proctor Study^e—Infliximab^Citation1	56 (35–75)	82 (63–94)	70 (47–87)		33 (17–54)	61 (41–79)	61 (39–80)	0.26/PY
Proctor Study—Adalimumab	38 (9–76)	75 (35–97)	57 (18–90)		38 (9–76)	63 (25–92)	57 (18–90)	0.26/PY

^aThe definition of control of inflammation differed in different studies and, as shown above, was either defined as no inflammation (MUST Trial) or as no or slight inflammation (SITE Cohort Studies, Proctor Study) on two separate visits separated by at least 28 days.

^bCorticosteroid sparing success defined as ≤10 mg/day.

^cDiscontinuation rates as shown include all reasons, including remission, which was generally low for all agents except cyclosphosphamide, where the discontinuation rate due to remission was 0.32/PY (0.24/PY.0.41/PY). Discontinue due to adverse events was generally one-third the overall discontinuation rate, except for cyclophosphamide, where discontinuation due to adverse events accounted for nearly half of all discontinuations.

^dSITE Study Group rates for all chronic noninfectious ocular inflammation, including, but not limited to, anterior, intermediate, and posterior/panuveitis. Includes scleritis, mucous membrane pemphigoid, and other less-common conditions.

^eMUST Trial Research Group rates for chronic noninfectious intermediate, posterior, and panuveitis.

^fProctor study for chronic noninfectious uveitis, including anterior, intermediate, anterior and intermediate, and posterior/panuveitis.

Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148:500–509.e2.

 PubMed Web of Science ®Google Scholar

Gangaputra S, Newcomb CW, Liesegang TL, et al. Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116:2188–98.e1.

 PubMed Web of Science ®Google Scholar

Pujari SS, Kempen JH, Newcomb CW et al., Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117:356–365.

 PubMed Web of Science ®Google Scholar

Kaçmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117:576–584.

 PubMed Web of Science ®Google Scholar

Daniel E, Thorne JE, Newcomb CW et al., Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149:423–32.e1.

 PubMed Web of Science ®Google Scholar

Kempen JH, Altaweel MM, Holbrook JT, et al. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology.2011; 118:1916–1926. Epub 2011 Aug 15.

 PubMed Web of Science ®Google Scholar

Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012;18–26.

 PubMedGoogle Scholar